AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9860147 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (0.5 mg) at pH 5
Number of subjects: 6
Study 9860147 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (0.5 mg) at pH 6
Number of subjects: 6
Study 9860147 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (0.06 mmol x l(‐1)) with cephradine (0.05 mmol x l(‐1))
Number of subjects: 6
Study 9860147 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (0.057 mmol x l(‐1)) with cephradine (0.05 mmol x l(‐1))
Number of subjects: 6
Study 7884114 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium fiber (Metamucil) 3.4 g
Number of subjects: 15
Study 7884114 — intervention group
Group type: COMPARATOR
Intervention: Neutral cellulose
Number of subjects: 15
Study 7884114 — intervention group
Group type: COMPARATOR
Intervention: No added fiber
Number of subjects: 15
Study 2404487 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.008% timolol ophthalmic solution
Number of subjects: 0
Study 2404487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2404487 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% timolol ophthalmic solution
Number of subjects: 0
Study 57570 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide phosphate
Number of subjects: 20
Study 57570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31040122 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 817
Study 31040122 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg biweekly
Number of subjects: 817
Study 31040122 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (rescued patients)
Number of subjects: 817
Study 31040122 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (rescued patients)
Number of subjects: 817
Study 31040122 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (switched from adalimumab)
Number of subjects: 817
Study 31040122 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib and Adalimumab (continuing treatment)
Number of subjects: 817
Study 28542164 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing information to late payers
Number of subjects: 4298
Study 25322473 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (N=63)
Number of subjects: 132
Study 25322473 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group, N=65)
Number of subjects: 132
Study 23556434 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Programme (HeLP)
Number of subjects: 1300
Study 21576561 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 21
Study 19891014 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization transfer imaging (MTI)
Number of subjects: 19
Study 19891014 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 19
Study 17383283 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive treatment strategy
Number of subjects: 1141
Study 17383283 — intervention group
Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 1141
Study 17383283 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP (highest quartile > or = 1170 ng/L for men, > or = 2150 ng/L for women)
Number of subjects: 1141
Study 17383283 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP (lower 3 quartiles)
Number of subjects: 1141
Study 17383283 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels
Number of subjects: 1141
Study 15576015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg administered orally under fasting conditions
Number of subjects: 6
Study 15576015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg administered orally under fed conditions
Number of subjects: 6
Study 15576015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg administered orally with food
Number of subjects: 6
Study 15576015 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 6
Study 11236774 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation of human embryonic dopamine neurons
Number of subjects: 40
Study 11236774 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 40
Study 11236774 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation of human embryonic dopamine neurons (younger patients)
Number of subjects: 40
Study 9604553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch treatment
Number of subjects: 0
Study 8085581 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and trace minerals
Number of subjects: 0
Study 8085581 — intervention group
Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study 3242578 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (0.009 mg kg‐1 subcutaneous route)
Number of subjects: 10
Study 3242578 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (0.30 mg kg‐1 i.v. route)
Number of subjects: 10
Study 3242578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17894079 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 0
Study 17894079 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 17894079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30851091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pallidal deep brain stimulation
Number of subjects: 105
Study 28052841 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based guided self-help intervention (cognitive-behavioral therapy and problem-solving therapy) in addition to usual care
Number of subjects: 406
Study 28052841 — intervention group
Group type: COMPARATOR
Intervention: Usual care supplemented with Web-based psycho-education (enhanced usual care)
Number of subjects: 406
Study 28052841 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based guided self-help intervention
Number of subjects: 406
Study 25848812 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance‐ and commitment‐based group (ACT + FB)
Number of subjects: 138
Study 25848812 — intervention group
Group type: COMPARATOR
Intervention: Feedback group (FB)
Number of subjects: 138
Study 23578686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitii training (20 weeks, 30 min daily)
Number of subjects: 0
Study 23578686 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (20 weeks)
Number of subjects: 0
Study 23578686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitii training
Number of subjects: 0
Study 22134973 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole + Divalproex
Number of subjects: 83
Study 22134973 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Divalproex
Number of subjects: 83
Study 20134038 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 458
Study 16769956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists
Number of subjects: 297
Study 16769956 — intervention group
Group type: COMPARATOR
Intervention: No dopamine agonists
Number of subjects: 297
Study 16769956 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent D3 receptor agonist
Number of subjects: 297
Study 15315398 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape seed extract (1000 mg/day total polyphenols)
Number of subjects: 69
Study 15315398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 11503008 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg, 3 times daily for 4 days)
Number of subjects: 9
Study 11503008 — intervention group
Group type: COMPARATOR
Intervention: DHEC (10 mg, administered alone)
Number of subjects: 9
Study 9250182 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (CHART) - 36 fractions of 1.5 Gy given three times per day for a total of 54 Gy in 12 days
Number of subjects: 563
Study 9250182 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy - 30 fractions of 2 Gy for a total dose of 60 Gy in 6 weeks
Number of subjects: 563
Study 8487006 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt intake (2.8 +/- 1.0 g day-1 of NaCl)
Number of subjects: 30
Study 8487006 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt supplements (11.7 +/- 2.5 g day-1 of NaCl)
Number of subjects: 30
Study 3661951 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of an opioid prior to methohexital and addition of lidocaine to the methohexital solution
Number of subjects: 0
Study 3661951 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study 3661951 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 0
Study 29895330 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5-10 mg/day)
Number of subjects: 340
Study 29895330 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (50-100 mg/day)
Number of subjects: 340
Study 29895330 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 340
Study 29895330 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 340
Study 26710224 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine 2% gel
Number of subjects: 60
Study 26710224 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study 25198032 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard endoscopic monitor with AR navigation displayed on a submonitor (SM)
Number of subjects: 50
Study 25198032 — intervention group
Group type: COMPARATOR
Intervention: AR as a single display
Number of subjects: 50
Study 22641307 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 72
Study 22641307 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 72
Study 20717951 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine with montelukast
Number of subjects: 275
Study 20717951 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine alone
Number of subjects: 275
Study 20717951 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine with placebo
Number of subjects: 275
Study 19025037 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal pain stimulation (46 degrees C for 6 min)
Number of subjects: 60
Study 19025037 — intervention group
Group type: COMPARATOR
Intervention: No pain stimulation
Number of subjects: 60
Study 16354850 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA-rich supplement (400 kilocalories per day)
Number of subjects: 64
Study 16354850 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA-rich supplement
Number of subjects: 64
Study 16354850 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 PUFA-nonrich supplement
Number of subjects: 64
Study 12552051 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.75 mg
Number of subjects: 305
Study 12552051 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 5.5 mg
Number of subjects: 305
Study 12552051 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 8.25 mg
Number of subjects: 305
Study 12552051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 14578939 — intervention group
Group type: EXPERIMENTAL
Intervention: In-situ radiofrequency ablation (RA)
Number of subjects: 40
Study 14578939 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy (MM)
Number of subjects: 40
Study 9448552 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 400 mg 4 times daily
Number of subjects: 313
Study 9448552 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg 4 times daily
Number of subjects: 313
Study 9448552 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (dosage titrated to achieve trough concentrations of 8 to 15 micrograms/mL)
Number of subjects: 313
Study 9448552 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both zileuton dosages and theophylline)
Number of subjects: 313
Study 9448552 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 313
Study 8537988 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 0
Study 2615523 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning intravenous administration of 4' epi-adriamycin (45 mg m-2)
Number of subjects: 10
Study 2615523 — intervention group
Group type: COMPARATOR
Intervention: Afternoon intravenous administration of 4' epi-adriamycin (45 mg m-2)
Number of subjects: 10
Study 2615523 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning and afternoon dosing of 4' epi-adriamycin
Number of subjects: 10
Study 342181 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride mouthrinse (100 parts/10(6)F‐)
Number of subjects: 1200
Study 342181 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride mouthrinse (200 parts/10(6)F‐)
Number of subjects: 1200
Study 342181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 30198084 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye screening (50%)
Number of subjects: 3039
Study 30198084 — intervention group
Group type: COMPARATOR
Intervention: Control (50%)
Number of subjects: 3039
Study 28672291 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERACT training and support
Number of subjects: 36717
Study 28672291 — intervention group
Group type: COMPARATOR
Intervention: Control group (no INTERACT training)
Number of subjects: 36717
Study 25366811 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated programme (AP)
Number of subjects: 51
Study 25366811 — intervention group
Group type: COMPARATOR
Intervention: Standard programme (SP)
Number of subjects: 51
Study 23644953 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min film based on intergroup contact theory
Number of subjects: 925
Study 23644953 — intervention group
Group type: EXPERIMENTAL
Intervention: Film based on a protest message
Number of subjects: 925
Study 23644953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 925
Study 21983248 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA (25 μg)
Number of subjects: 27
Study 21983248 — intervention group
Group type: COMPARATOR
Intervention: F/U (follow-up)
Number of subjects: 27
Study 21983248 — intervention group
Group type: COMPARATOR
Intervention: IVB (1.25 mg of bevacizumab)
Number of subjects: 27
Study 19366494 — intervention group
Group type: EXPERIMENTAL
Intervention: New Clinical Pathway (NCP)
Number of subjects: 3434
Study 19366494 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 3434
Study 16448621 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC-tandem mass spectrometry (HPLC-MS-MS) for quantitation of plasma total 15-series PGF isomers and AA
Number of subjects: 0
Study 16448621 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC-MS-MS
Number of subjects: 0
Study 15265286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured artificial bone grafted into the abdominal cavity of nude mice
Number of subjects: 27
Study 15265286 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous ceramics impregnated with marrow cells subcultured in osteogenic culture medium
Number of subjects: 27
Study 10678339 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular vaginal pH testing
Number of subjects: 121
Study 10678339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal symptoms or pH level >4.5
Number of subjects: 121
Study 9279201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate NaCl diet (120 mmol)
Number of subjects: 30
Study 9279201 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NaCl diet (20 mmol)
Number of subjects: 30
Study 9279201 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl diet (240 mmol)
Number of subjects: 30
Study 8285365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (endovenous)
Number of subjects: 72
Study 8285365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (intramuscular)
Number of subjects: 72
Study 8285365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (rectal)
Number of subjects: 72
Study 8285365 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (control group)
Number of subjects: 72
Study 30359300 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli (Lactobacillus reuteri)
Number of subjects: 10
Study 30359300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 27121699 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous moderate intensity aerobic exercise (CAE) for 30 minutes at 50% of maximum aerobic work
Number of subjects: 20
Study 27121699 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval aerobic exercise (hIAE) for 30 minutes at maximum aerobic work
Number of subjects: 20
Study 24480902 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the randomized double-blind placebo-controlled trial (Sugar Babies Study)
Number of subjects: 481
Study 24480902 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care (heel lance blood tests)
Number of subjects: 481
Study 22921698 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vardenafil 10 mg
Number of subjects: 74
Study 20351239 — intervention group
Group type: EXPERIMENTAL
Intervention: Study protocol (Guidelines 2005)
Number of subjects: 845
Study 20351239 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (Guidelines 2000)
Number of subjects: 845
Study 18514907 — intervention group
Group type: EXPERIMENTAL
Intervention: Urtica dioica (nettle sting) daily for 1 week
Number of subjects: 42
Study 18514907 — intervention group
Group type: COMPARATOR
Intervention: Urtica galeopsifolia (placebo) daily for 1 week
Number of subjects: 42
Study 15452188 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 U once weekly)
Number of subjects: 354
Study 12616254 — intervention group
Group type: EXPERIMENTAL
Intervention: New MOW program (3 meals and 2 snacks per day, 7 days a week, meeting 100% of the Daily Reference Intake)
Number of subjects: 203
Study 12616254 — intervention group
Group type: COMPARATOR
Intervention: Traditional MOW program (5 hot meals per week, meeting 33% of the Daily Reference Intake)
Number of subjects: 203
Study 10806125 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB procedure using a suction device and regular sternotomy
Number of subjects: 26
Study 10806125 — intervention group
Group type: COMPARATOR
Intervention: CABG using extracorporeal circulation, blood cardioplegia and hypothermic arrest
Number of subjects: 26
Study 10806125 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB procedure
Number of subjects: 26
Study 10806125 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 26
Study 10806125 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 26
Study 8915025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% chlorhexidine
Number of subjects: 25
Study 8915025 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% co-polymer and 0.03% chlorhexidine
Number of subjects: 25
Study 8915025 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% co-polymer
Number of subjects: 25
Study 8915025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 25
Study 8915025 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 1802131 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection
Number of subjects: 30
Study 6412266 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 0
Study 6412266 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 0
Study 31653265 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Number of subjects: 10
Study 31653265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS
Number of subjects: 10
Study 31653265 — intervention group
Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 10
Study 31653265 — intervention group
Group type: EXPERIMENTAL
Intervention: C3-T3 montage
Number of subjects: 10
Study 29384020 — intervention group
Group type: EXPERIMENTAL
Intervention: Wup34min (warm-up protocol of 34 min)
Number of subjects: 18
Study 29384020 — intervention group
Group type: COMPARATOR
Intervention: Wup17min (warm-up protocol of 17 min)
Number of subjects: 18
Study 29384020 — intervention group
Group type: EXPERIMENTAL
Intervention: Both warm-up protocols (Wup34min and Wup17min)
Number of subjects: 18
Study 29384020 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perceived muscular load (RPEMUSC)
Number of subjects: 18
Study 26554025 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (potent irreversible P2Y12 inhibitor)
Number of subjects: 20
Study 26554025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26554025 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 20
Study 24980739 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia restorations
Number of subjects: 22
Study 24980739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium disilicate crowns
Number of subjects: 22
Study 24980739 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal ceramic crowns
Number of subjects: 22
Study 24980739 — intervention group
Group type: COMPARATOR
Intervention: Control group (unprepared or minimally restored tooth)
Number of subjects: 22
Study 21924563 — intervention group
Group type: COMPARATOR
Intervention: Brief advice by the practitioner
Number of subjects: 3086
Study 21924563 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored computer‐generated letters
Number of subjects: 3086
Study 21924563 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both interventions
Number of subjects: 3086
Study 21924563 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored letters
Number of subjects: 3086
Study 20644019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6560
Study 18271227 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese drugs acupoint injection (Danshen Injection and Chaihu Injection)
Number of subjects: 150